Company intelligence / Profile preview

HemoShear Therapeutics

Charlottesville, Virginia, United Statesleadiq.com ↗

Ownership: Private
Employees: ~40
Development stage: Phase 2

Overview

HemoShear’s lead candidate HST5040 has completed or is completing a Phase 2 study in MMA and PA. The compound has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA. The company also has preclinical programs targeting cholestasis disorders and hepatitis D with novel small molecules. Collaborations have validated their REVEAL-Tx™ platform in NASH and gout.

Therapeutic areas: GastroenterologyInfectious DiseasesMetabolic DisordersRheumatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

HST-28468

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Takeda Pharmaceutical Company (NASH)Horizon Therapeutics plc. (gout)Suvretta Capital as major investor/sponsor of clinical studies

Beyond the preview

Go deeper on HemoShear Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HemoShear Therapeutics.

Explore the full profile